. Author manuscript; available in PMC: 2010 May 3.

Published in final edited form as: Gene Ther. 2008 May 1;15(17):1210–1222. doi: 10.1038/gt.2008.73

Table 1.

Design of antiviral vectors derived from M87o and control vector.

Vector	Leader region^a	C46 sequence	Hinge	Membrane spanning domain	Marker	Cis element	Expression PM-1/PBMC
M87o_HIV	MP71	HIV-1 HXB2	Human IgG2	Human CD34	---	wPRE/RRE	+++/+++
M87o_SHIV	MP71	SHIV89.6P	Human IgG2	Human CD34	---	wPRE/RRE	+++/+++
M87o_SIV	MP71	SIVmac239	Human IgG2	Human CD34	---	wPRE/RRE	+++/+++
M87o_HIV low	MP71	HIV-1 HXB2	Human IgG2	Human CD34	IRES Neo	---	+/n.d.
M87o_SHIV low	MP71	SHIV89.6P	Human IgG2	Human CD34	IRES Neo	---	+/n.d.
M87o_SIV low	MP71	SIVmac239	Human IgG2	Human CD34	IRES Neo	---	+/n.d.
Neo control	MP1	---	---	---	IRES Neo	---	n.a./n.a.
Inactive C46	MP91	mutated + 2F5 epitope	Human IgG2	Human CD34	---	---	+++/n.d.

The leader regions of the vectors were described elsewhere.¹⁹, ²⁸